Posted by Michael Wonder on 25 May 2023
Milvexian granted US FDA fast track designation for all three indications under evaluation in Phase 3 Librexia program: ischaemic stroke, acute coronary syndrome and atrial fibrillation
25 May 2023 - The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, with all three studies underway.
BMS, in collaboration with Janssen, today announced that all three prospective indications for milvexian, an investigational oral factor XIa inhibitor, have now been granted fast track designation by the US FDA.
